BioPorto Diagnostics (US) Revenue
Biotechnology Research • 
Boston, Massachusetts, United States • 11-20 Employees
BioPorto Diagnostics (US) revenue & valuation
| Annual revenue | $1,711,100 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $5,500,000 |
| Total funding | No funding |
Key Contacts at BioPorto Diagnostics (US)
Matt Grimmig
Business Development Director - Us & Canada
Prasad Devarajan
Senior Medical Director
Company overview
| Headquarters | Boston, Massachusetts, United States |
| Website | |
| NAICS | 541714 |
| Keywords | Clinical Research, Fda Qualified Biomarker (Bqp), Drug Induced Kidney Injury (Diki), Scientific And Pre-Clinical Drug Research, Kidney Disease Research, Ngal Elisa Kits (Human And Animal), Ngal Research, Pre-Clinical / Non-Clinical Research, Aki Management, Kidney Damage Test, Ngal Test |
| Employees | 11-20 |
| Socials |
BioPorto Diagnostics (US) Email Formats
BioPorto Diagnostics (US) uses 1 email format. The most common is {2char} (e.g., {2char}@bioporto.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{2char} | {2char}@bioporto.com | 100% |
About BioPorto Diagnostics (US)
Acute kidney injury (AKI) is a common clinical syndrome among hospitalized patients, affecting 10-15% of hospitalized patients, and 25-57% of those in intensive care units.. It is often asymptomatic and can be difficult to identify, yet it can have severe short- and long-term consequences. To learn more about this public health concern, visit https://bioporto.us/aki/. Located outside Boston, BioPorto Diagnostics is focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. FDA-cleared ProNephro AKI™ (NGAL) is designed to aid in AKI risk assessment in pediatric patients ≥ 3 months to <22 years of age by providing quantitative determinations of the NGAL biomarker (neutrophil gelatinase-associated lipocalin). Learn more about ProNephro AKI™ (NGAL) at: https://bioporto.us/pronephro-aki/ Posts are intended for a U.S. audience. If you are from outside the United States, you are encouraged to visit www.bioporto.com to learn more about The NGAL Test™ which is CE-Marked for IVD use in the EU and to follow BioPorto Diagnostics A/S on LinkedIn at https://www.linkedin.com/company/bioporto-diagnostics-a-s/ Social Media Community Guidelines: https://bioporto.us/social-media
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
BioPorto Diagnostics (US) has 10 employees across 5 departments.
Departments
Number of employees
Funding Data
BioPorto Diagnostics (US) has never raised funding before.
BioPorto Diagnostics (US) Tech Stack
Discover the technologies and tools that power BioPorto Diagnostics (US)'s digital infrastructure, from frameworks to analytics platforms.
Video players
Security
JavaScript frameworks
JavaScript libraries
JavaScript libraries
UI frameworks
JavaScript libraries
Page builders
JavaScript libraries
CDN
JavaScript graphics
JavaScript libraries
United Kingdom
Australia
Guadeloupe
Frequently asked questions
4.8
40,000 users
